[go: up one dir, main page]

NO980209D0 - Ny fremgangsmåte for fremstilling av amorft £R-(R*,R*)|-2-(4-fluorfenyl)-<beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-£(fenylamino)karbonyl|-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) - Google Patents

Ny fremgangsmåte for fremstilling av amorft £R-(R*,R*)|-2-(4-fluorfenyl)-<beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4-£(fenylamino)karbonyl|-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1)

Info

Publication number
NO980209D0
NO980209D0 NO980209A NO980209A NO980209D0 NO 980209 D0 NO980209 D0 NO 980209D0 NO 980209 A NO980209 A NO 980209A NO 980209 A NO980209 A NO 980209A NO 980209 D0 NO980209 D0 NO 980209D0
Authority
NO
Norway
Prior art keywords
phenylamino
fluorophenyl
pyrrole
carbonyl
amorphous
Prior art date
Application number
NO980209A
Other languages
English (en)
Other versions
NO309322B1 (no
NO980209L (no
Inventor
Dieter Schweiss
Min Lin
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21696097&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO980209(D0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of NO980209D0 publication Critical patent/NO980209D0/no
Publication of NO980209L publication Critical patent/NO980209L/no
Publication of NO309322B1 publication Critical patent/NO309322B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pyrrole Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
NO980209A 1995-07-17 1998-01-16 Fremgangsmåte for fremstilling av amorft [R-(R*,R*)]-2-(4- fluorfenyl)-<beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1) NO309322B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US145395P 1995-07-17 1995-07-17
PCT/US1996/011807 WO1997003960A1 (en) 1995-07-17 1996-07-16 NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS [R-(R*,R*)]-2-(4-FLUOROPHENYL)-β,δ-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID CALCIUM SALT (2:1)

Publications (3)

Publication Number Publication Date
NO980209D0 true NO980209D0 (no) 1998-01-16
NO980209L NO980209L (no) 1998-01-16
NO309322B1 NO309322B1 (no) 2001-01-15

Family

ID=21696097

Family Applications (1)

Application Number Title Priority Date Filing Date
NO980209A NO309322B1 (no) 1995-07-17 1998-01-16 Fremgangsmåte for fremstilling av amorft [R-(R*,R*)]-2-(4- fluorfenyl)-<beta>,<delta>-dihydroksy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1)

Country Status (37)

Country Link
US (1) US6274740B1 (no)
EP (1) EP0839132B1 (no)
JP (1) JP4064459B2 (no)
KR (1) KR100400805B1 (no)
CN (1) CN1087289C (no)
AR (1) AR002849A1 (no)
AT (1) ATE199542T1 (no)
AU (1) AU700794B2 (no)
BG (1) BG63631B1 (no)
BR (1) BR9609714A (no)
CA (1) CA2220455C (no)
CO (1) CO4700441A1 (no)
CZ (1) CZ289421B6 (no)
DE (1) DE69611999T2 (no)
DK (1) DK0839132T5 (no)
EA (1) EA000625B1 (no)
EE (1) EE03605B1 (no)
ES (1) ES2156997T3 (no)
GE (1) GEP20002027B (no)
GR (1) GR3035859T3 (no)
HR (1) HRP960312B1 (no)
HU (1) HU220343B (no)
IL (1) IL122161A (no)
IN (1) IN185276B (no)
MX (1) MX9708959A (no)
NO (1) NO309322B1 (no)
NZ (1) NZ313008A (no)
PE (1) PE1698A1 (no)
PL (1) PL191017B1 (no)
PT (1) PT839132E (no)
RO (1) RO120069B1 (no)
SI (1) SI0839132T1 (no)
SK (1) SK283204B6 (no)
UA (1) UA50743C2 (no)
UY (1) UY24286A1 (no)
WO (1) WO1997003960A1 (no)
ZA (1) ZA966043B (no)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
IN191236B (no) 1999-05-25 2003-10-11 Ranbaxy Lab Ltd
HU226640B1 (en) * 1999-10-18 2009-05-28 Egis Gyogyszergyar Nyilvanosan Process for producing amorphous atorvastatin calcium salt
US6646133B1 (en) 2000-10-17 2003-11-11 Egis Gyogyszergyar Rt. Process for the preparation of amorphous atorvastatin calcium
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
SI20425A (sl) * 1999-12-10 2001-06-30 LEK tovarna farmacevtskih in kemi�nih izdelkov d.d. Priprava amorfnega atorvastatina
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
CZ20032019A3 (cs) 2000-12-27 2003-10-15 Ciba Specialty Chemicals Holding Inc. Krystalické formy Atorvastatinu
WO2002057228A1 (en) * 2001-01-17 2002-07-25 Biocon India Limited Atorvastatin calcium
WO2002057229A1 (en) 2001-01-19 2002-07-25 Biocon India Limited FORM V CRYSTALLINE [R-(R*,R*)]-2-(4-FLUOROPHENYL)-ß,$G(D)-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1- HEPTANOIC ACID HEMI CALCIUM SALT. (ATORVASTATIN)
SI20814A (sl) * 2001-01-23 2002-08-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Priprava amorfnega atorvastatina
SI20848A (sl) 2001-03-14 2002-10-31 Lek, Tovarna Farmacevtskih In Kemijskih Izdelkov, D.D. Farmacevtska formulacija, ki vsebuje atorvastatin kalcij
IN190564B (no) * 2001-04-11 2003-08-09 Cadila Heathcare Ltd
IL158790A0 (en) 2001-06-29 2004-05-12 Warner Lambert Co Crystalline forms of [r-(*,r*)]-2-(4-fluorophenyl) -beta, delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino) carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) (atorvastatin)
US7361772B2 (en) 2001-08-16 2008-04-22 Biocon Limited Process for the production of atorvastatin calcium
EP1572638A4 (en) 2001-08-31 2010-05-05 Morepen Lab Ltd IMPROVED METHOD FOR THE PRODUCTION OF AMORPHIC ATORVASTATIN CALCIUM SALT (2: 1)
UA77990C2 (en) * 2001-12-12 2007-02-15 Crystalline calcium salt of (2:1) [r-(r*,r*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrroleheptanic acid
CZ296967B6 (cs) * 2002-02-01 2006-08-16 Zentiva, A.S. Zpusob výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu)
IL164020A0 (en) * 2002-03-18 2005-12-18 Biocon Ltd A process for the preparation of amorphous hmg-coareductase inhibitors
RU2309141C2 (ru) * 2002-03-18 2007-10-27 Байокон Лимитид АМОРФНЫЕ ИНГИБИТОРЫ ГМГ-КоА-РЕДУКТАЗЫ И СПОСОБ ИХ ПОЛУЧЕНИЯ
ITMI20020907A1 (it) * 2002-04-29 2003-10-29 Chemi Spa Processo di preparazione della forma amorfa del sale di calcio della atorvastatina
WO2003099785A1 (en) * 2002-05-28 2003-12-04 Cadila Healthcare Limited Process for the preparation of amorphous atorvastatin calcium
US7179942B2 (en) 2002-07-05 2007-02-20 Bicon Limited Halo-substituted active methylene compounds
AU2002330735A1 (en) * 2002-09-03 2004-03-29 Morepen Laboratories Limited Atorvastatin calcium form vi or hydrates thereof
WO2004089895A1 (en) * 2003-04-11 2004-10-21 Lek Pharmaceuticals D.D. Process for the preparation of amorphous calcium salt of atorvastatin
US7232920B2 (en) 2003-04-22 2007-06-19 Biocon Process for stereoselective reduction of β-ketoesters
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
AU2003272080A1 (en) 2003-09-18 2005-04-06 Biocon Limited Novel process for the preparation of tert-butyl 6-cyano-5-hydroxy-3-oxohexanoate
CA2456430A1 (en) * 2004-01-28 2005-07-28 Brantford Chemicals Inc. Improved process for the preparation of amorphous atorvastatin calcium
CZ298382B6 (cs) * 2004-03-10 2007-09-12 Zentiva, A. S. Zpusob prípravy amorfní formy hemivápenaté soli atorvastatinu a její stabilizace
EP1727795B1 (en) * 2004-03-17 2012-02-15 Ranbaxy Laboratories Limited Process for the production of atorvastatin calcium in amorphous form
JP2007536373A (ja) 2004-05-05 2007-12-13 ファイザー・プロダクツ・インク アトルバスタチンの塩形態
JP5000502B2 (ja) * 2004-07-16 2012-08-15 レツク・フアーマシユーテイカルズ・デー・デー アトルバスタチンカルシウムの酸化分解生成物
CA2578722C (en) 2004-08-27 2010-02-02 Biocon Limited Process for atorvastatin calcium amorphous
US20080009540A1 (en) * 2004-09-30 2008-01-10 Srinivasulu Gudipati Amorphous Atorvastatin Calcium
EP1716114A1 (en) * 2004-10-18 2006-11-02 Teva Pharmaceutical Industries Ltd. Process for preparing amorphous atorvastatin hemi-calcium by dissolving the salt in an organic solvent which is a mixture of an alcohol and a ketone and/or an ester and removing the solvent
AU2005298383A1 (en) * 2004-10-28 2006-05-04 Warner-Lambert Company Llc Process for forming amorphous atorvastatin
WO2006054308A2 (en) 2004-11-22 2006-05-26 Dexcel Pharma Technologies Ltd. Stable atorvastatin formulations
US20090088465A1 (en) * 2004-12-02 2009-04-02 Stephen Craig Dyar Pharmaceutical Compositions of Amorphous Atorvastatin and Process for Preparing Same
US20080108664A1 (en) * 2005-12-23 2008-05-08 Liu Belle B Solid-state form of AMG 706 and pharmaceutical compositions thereof
EP1810667A1 (en) 2006-01-20 2007-07-25 KRKA, tovarna zdravil, d.d., Novo mesto Pharmaceutical composition comprising amorphous atorvastatin
CA2640573A1 (en) * 2006-03-01 2007-09-13 Michael Pinchasov Process for preparing a crystalline form of atorvastatin hemi-calcium
US20100113802A1 (en) * 2006-11-02 2010-05-06 Cadila Pharmaceuticals Limited Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate
US7834195B2 (en) 2007-01-24 2010-11-16 Apotex Pharmachem Inc. Atorvastatin calcium propylene glycol solvates
WO2009007856A2 (en) * 2007-07-11 2009-01-15 Actavis Group Ptc Ehf Novel polymorph of atorvastatin calcium and use thereof for the preparation of amorphous atorvastatin calcium
US20090124817A1 (en) * 2007-11-09 2009-05-14 The Industry & Academic Cooperation In Chungnam National University Process for Preparing Amorphous Atorvastatin Calcium Nanoparticles
EP2075246A1 (en) 2007-12-27 2009-07-01 M. J. Institute of Research A process for preparation of amorphous form of atorvastatin hemi-calcium salt
WO2010066846A2 (en) * 2008-12-11 2010-06-17 Dsm Ip Assets B.V. Method for the isolation of atorvastatin
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
CZ201039A3 (cs) 2010-01-19 2011-07-27 Zentiva, K. S Zpusob prumyslové výroby amorfní formy hemivápenaté soli (3R,5R) 7-[3-fenyl-4-fenylkarbamoyl-2-(4-fluorfenyl)-5-isopropylpyrrol-1-yl]-3,5-dihydroxyheptanové kyseliny (atorvastatinu) s vysokým specifickým povrchem a jeho použití v lékové forme

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) * 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
CZ294108B6 (cs) 1995-07-17 2004-10-13 Warner@Lambertácompany Krystalická forma I hydrátu atorvastatinuŹ tj@ semivápenaté soli kyseliny [R@}RgŹRgB]@}@fluorfenylB@betaŹdelta@dihydroxy@Q@}�@methylethylB@fenyl[}fenylaminoBkarbonyl]@�H@pyrrol@�@heptanové

Also Published As

Publication number Publication date
ZA966043B (en) 1997-02-03
RO120069B1 (ro) 2005-08-30
SK5898A3 (en) 1998-08-05
GEP20002027B (en) 2000-04-10
CN1190956A (zh) 1998-08-19
PT839132E (pt) 2001-06-29
KR100400805B1 (ko) 2003-12-24
CZ289421B6 (cs) 2002-01-16
DE69611999D1 (de) 2001-04-12
HU220343B (hu) 2001-12-28
US6274740B1 (en) 2001-08-14
JPH11510486A (ja) 1999-09-14
PL324463A1 (en) 1998-05-25
BR9609714A (pt) 1999-02-23
BG63631B1 (bg) 2002-07-31
MX9708959A (es) 1998-03-31
EA000625B1 (ru) 1999-12-29
DE69611999T2 (de) 2001-07-26
AU700794B2 (en) 1999-01-14
DK0839132T5 (da) 2006-03-20
UA50743C2 (uk) 2002-11-15
KR19990029045A (ko) 1999-04-15
EP0839132A1 (en) 1998-05-06
AR002849A1 (es) 1998-04-29
CA2220455A1 (en) 1997-02-06
EP0839132B1 (en) 2001-03-07
IL122161A0 (en) 1998-04-05
NO309322B1 (no) 2001-01-15
UY24286A1 (es) 1997-01-17
ATE199542T1 (de) 2001-03-15
CZ12298A3 (cs) 1998-12-16
DK0839132T3 (da) 2001-04-09
PE1698A1 (es) 1998-02-19
SK283204B6 (sk) 2003-03-04
EE9700369A (et) 1998-06-15
IL122161A (en) 1999-07-14
IN185276B (no) 2000-12-16
HRP960312A2 (en) 1998-02-28
JP4064459B2 (ja) 2008-03-19
NO980209L (no) 1998-01-16
HK1018054A1 (en) 1999-12-10
CA2220455C (en) 2002-09-24
AU6497896A (en) 1997-02-18
EA199800128A1 (ru) 1998-08-27
NZ313008A (en) 2000-01-28
SI0839132T1 (no) 2001-06-30
HUP9903017A3 (en) 2001-01-29
WO1997003960A1 (en) 1997-02-06
HRP960312B1 (en) 2001-10-31
BG102188A (en) 1998-08-31
CO4700441A1 (es) 1998-12-29
ES2156997T3 (es) 2001-08-01
PL191017B1 (pl) 2006-03-31
CN1087289C (zh) 2002-07-10
GR3035859T3 (en) 2001-08-31
EE03605B1 (et) 2002-02-15

Similar Documents

Publication Publication Date Title
NO980209L (no) Ny fremgangsmåte for fremstilling av amorft £R-(R*,R*)|-2-(4-fluorfenyl)-&lt;beta&gt;,&lt;delta&gt;-dihydroksy-5-(1-metyletyl)-3-fenyl-4-£(fenylamino)karbonyl|-1H-pyrrol-1-heptansyre-kalsiumsalt (2:1)
HUP9802578A3 (en) Phenylacetic acid derivatives, process and intermediates for producing them, fingicide, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients and use thereof
NO980207D0 (no) Krystallinsk £R-(R*,R*)|-2-(4-fluorfenyl)-&lt;beta&gt;,&lt;delta&gt;-dihydroksy-5-(1-metyletyl)-3-fenyl-4-£(fenylamino)karbonyl|-1-H-pyrrol-1-heptansyrehemikalsiumsalt (Atorvastatin)
HUT70526A (en) Indole-2-carboxylic acid derivatives, process for producing thereof and pharmaceutical compositions comprising same compounds
AU7562296A (en) Novel amino acid derivatives, methods of producing them, and pharmaceutical compounds containing these compounds
HUT54275A (en) Fungicidal compositions comprising substituted amino acid amide derivatives and process for producing such compounds
ZA968956B (en) Substituted 2,4-imidazolidinedione compounds as pharmaceutical active ingredients
HUP0000728A3 (en) Salt of naphthyridine carboxylic acid derivative, process for producing it and pharmaceutical composition containing it
HUP9901065A3 (en) New barbituric acid derivatives, pharmaceutical compositions containing these compounds and process for producing them
IL115072A (en) Pharmaceutical compositions containing substituted 4-phenyl-6-amino-nicotinic acid derivatives their preparation some such new compounds and process for their preparation
HUP9800087A3 (en) Alkoximino acetic acid amides, pesticidal compositions containing them, method for combating pests and process for the preparation of the compounds
AU2001284385A1 (en) An improved process for the preparation of amorphous atorvastatin calcium salt (2:1)
HU9303030D0 (en) Process for preparation of l-5-(2-acetoxi-propionyl-amino)-2,4,6-trijodo-dichloro-isophtalic acid
HU9602072D0 (en) Substituted cinnamic acid guanidines, process for producing them, and pharmaceutical compositions containing them
AU3950095A (en) Compositions and methods for detection of 2,4-dichlorophenoxyacetic acid and related compounds
AU6058496A (en) New aminophenylphosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them
AU3407597A (en) Useful formulations of acid addition salt drugs
EE03393B1 (et) Protsess enantiomeerselt puhta asetidiin-2-karboksüülhappe saamiseks
AU3189197A (en) Agricultural compositions containing glycolic acid
NO975499D0 (no) Form III krystallinsk (R-(R*,R*)-2(4-fluorfenyl)-&lt;beta&gt;-&lt;delta&gt;-dihydroksy-(1-metyl-etyl)-3-fenyl-4-(fenylamino)karbonyl)-1H-pyrrol-1-heptansyre-hemi-kalsiumsalt
HUT58089A (en) Process for producing 3-(l-pyroglutamyl)-l-thiazolidine-4-carboxylic aci derivatives and pharmaceutical compositions comprising such compounds as active ingredient
HUP9602637A3 (en) 2-(4-pyrazolyloxy-pyrimidin-5-yl) acetic acid derivatives, producing and using them and fungicid compositions containing them
AU5635496A (en) Derivatives of 2,3:4,6-di-o-isopropylidene-alpha-l-xylo-2-he xulofluranosonic acid
AU642336B2 (en) Bisphosphonic acid derivatives, their intermediates and bone resorption inhibitors containing them as active ingredients
AU2806595A (en) Pyridonecarboxylic acid derivative, ester thereof, salt thereof, and intermediate for synthesis of these compounds